Lucid Diagnostics (NASDAQ:LUCD) Announces Earnings Results, Hits Expectations

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) posted its earnings results on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06), FiscalAI reports. The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.63 million.

Here are the key takeaways from Lucid Diagnostics’ conference call:

  • Medicare has begun paying for EsoGuard claims submitted through Lucid’s Texas lab, with Novitas allowing claims at the established rate of $1,938.01 per test. This claim-by-claim coverage is independent of the still-pending MolDX coverage decision and enables Lucid to pursue Medicare patients now.
  • Lucid reported a record October, with more than 1,800 tests performed and over 300 Medicare tests—nearly 70% of the Medicare volume recorded in all of Q3. Management said early commercial efforts are gaining traction, while cautioning that holiday seasonality makes it premature to extrapolate October’s pace across Q4.
  • Q3 revenue was $1.2 million, flat year over year and down from $1.5 million in Q2, despite 2,871 tests sold. Lucid recognized revenue equal to about 15% of the quarter’s stated billable value, and collections from non-Medicare insurers remain less predictable, although the average allowable amount on successful insurance claims improved.
  • Lucid expects five Concert client plans to adopt its EsoGuard coverage policy by year-end, with the policy set to cover nearly all commercial lives in Minnesota next month. The company also highlighted favorable draft AGA guidelines and said its first two VA programs are operating.
  • A post-quarter $15 million Series C financing brings pro forma cash to about $33 million, but its terms are dilutive: the conversion price is approximately $0.35 per share, and the preferred stock carries a 20% annual stock-paid dividend. Lucid estimated roughly 330 million fully diluted shares, excluding significantly out-of-the-money options.

Lucid Diagnostics Trading Up 14.6%

NASDAQ:LUCD traded up $0.06 on Friday, reaching $0.48. The stock had a trading volume of 2,105,279 shares, compared to its average volume of 2,368,255. The company has a 50-day moving average of $0.61 and a 200 day moving average of $0.99. The stock has a market cap of $96.95 million, a P/E ratio of -1.01 and a beta of 1.19. Lucid Diagnostics has a 12-month low of $0.30 and a 12-month high of $1.63.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. BTIG Research reiterated a “buy” rating on shares of Lucid Diagnostics in a research note on Thursday. Needham & Company LLC restated a “buy” rating on shares of Lucid Diagnostics in a report on Thursday, October 1st. Finally, Weiss Ratings cut shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lucid Diagnostics has a consensus rating of “Moderate Buy” and an average price target of $4.19.

Get Our Latest Report on LUCD

Recent Lucid Diagnostics Headlines

Here are a few of the latest headlines about LUCD:

  • Positive Sentiment: Lucid says EsoGuard is now fully reimbursed by Medicare nationwide at $1,938.01 per test, and reported record monthly test volume to start the fourth quarter. The company says this marks a new phase of commercial acceleration. Lucid Diagnostics Q3 2026 business update
  • Positive Sentiment: BTIG Research reaffirmed its “buy” rating, signaling continued analyst optimism. BTIG Research ratings
  • Neutral Sentiment: Third-quarter loss was $0.06 per share, in line with consensus and narrower than the $0.10 loss a year earlier. Lucid Diagnostics Q3 earnings report

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.

Read More

Earnings History for Lucid Diagnostics (NASDAQ:LUCD)

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.